<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Supernus Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/supernus-pharmaceuticals-inc</link>
<description>Latest news and press releases for Supernus Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 20:15:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/supernus-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c52d78dffbe2df11a7f6.webp</url>
<title>Supernus Pharmaceuticals Inc</title>
<link>https://6ix.com/company/supernus-pharmaceuticals-inc</link>
</image>
<item>
<title>Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026</title>
<link>https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-pharmaceuticals-to-announce-first-quarter-2026-financial-results-and-host-conference-call-on-may-5-2026</link>
<guid isPermaLink="true">https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-pharmaceuticals-to-announce-first-quarter-2026-financial-results-and-host-conference-call-on-may-5-2026</guid>
<pubDate>Wed, 22 Apr 2026 20:15:00 GMT</pubDate>
<description>ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report first quarter 2026 financial and business results after the market closes on Tuesday, May 5, 2026. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call and webcast on Tuesday,</description>
</item>
<item>
<title>Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-announces-record-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-announces-record-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Tue, 24 Feb 2026 21:05:00 GMT</pubDate>
<description>Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year. Combined revenues of the Company's four growth products increased to $161.3 million and $521.8 million in the fourth quarter and full year 2025, representing year-over-year growth of 45% and 40% respectively. The strong growth in both periods was driven by an increase in net sales of Qelbree® and GOCOVRI®, and the addition of sales from ZU</description>
</item>
<item>
<title>Supernus Pharmaceuticals to Participate in March Investor Conferences</title>
<link>https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-pharmaceuticals-to-participate-in-march-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-pharmaceuticals-to-participate-in-march-investor-conferences</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and</description>
</item>
<item>
<title>Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026</title>
<link>https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-pharmaceuticals-announce-fourth-quarter-213500789</link>
<guid isPermaLink="true">https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-pharmaceuticals-announce-fourth-quarter-213500789</guid>
<pubDate>Thu, 12 Feb 2026 21:35:00 GMT</pubDate>
<description>ROCKVILLE, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report fourth quarter and full year 2025 financial and business results after the market closes on Tuesday, February 24, 2026. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conf</description>
</item>
<item>
<title>Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference</title>
<link>https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-pharmaceuticals-participate-bank-america-securities-2025-cns-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-pharmaceuticals-participate-bank-america-securities-2025-cns-therapeutics</guid>
<pubDate>Wed, 03 Dec 2025 05:00:00 GMT</pubDate>
<description>ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and</description>
</item>
<item>
<title>Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-pharmaceuticals-participate-piper-sandler-37th-annual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-pharmaceuticals-participate-piper-sandler-37th-annual-healthcare-conference</guid>
<pubDate>Fri, 21 Nov 2025 05:00:00 GMT</pubDate>
<description>ROCKVILLE, Md., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and</description>
</item>
<item>
<title>Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London</title>
<link>https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-participate-2025-jefferies-global-healthcare-conference-london-2025-11-12</link>
<guid isPermaLink="true">https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-participate-2025-jefferies-global-healthcare-conference-london-2025-11-12</guid>
<pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
<description>ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and</description>
</item>
<item>
<title>Supernus Announces Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-announces-third-quarter-2025-financial-results-2025-11-04</link>
<guid isPermaLink="true">https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-announces-third-quarter-2025-financial-results-2025-11-04</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>Combined revenues of the Company's four growth products increased 52% to $149.2 million in the third quarter of 2025, compared to the same period in 2024.</description>
</item>
<item>
<title>Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025</title>
<link>https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-pharmaceuticals-announce-third-quarter-2025-financial-results-and-host</link>
<guid isPermaLink="true">https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-pharmaceuticals-announce-third-quarter-2025-financial-results-and-host</guid>
<pubDate>Tue, 21 Oct 2025 04:00:00 GMT</pubDate>
<description>ROCKVILLE, Md., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and</description>
</item>
<item>
<title>Supernus Pharmaceuticals to Participate in September Investor Conferences</title>
<link>https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-pharmaceuticals-participate-september-investor-conferences-2025-08-27</link>
<guid isPermaLink="true">https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-pharmaceuticals-participate-september-investor-conferences-2025-08-27</guid>
<pubDate>Wed, 27 Aug 2025 04:00:00 GMT</pubDate>
<description>ROCKVILLE, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and</description>
</item>
<item>
<title>Supernus Announces Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-announces-second-quarter-2025-financial-results-2025-08-06</link>
<guid isPermaLink="true">https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-announces-second-quarter-2025-financial-results-2025-08-06</guid>
<pubDate>Tue, 05 Aug 2025 04:00:00 GMT</pubDate>
<description>Net sales of Qelbree® increased 31% in the second quarter of 2025, compared to the same period in 2024. Net sales of Qelbree of $77.6 million and $142.3</description>
</item>
<item>
<title>Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics</title>
<link>https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-pharmaceuticals-completes-acquisition-sage-therapeutics-2025-07-31</link>
<guid isPermaLink="true">https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-pharmaceuticals-completes-acquisition-sage-therapeutics-2025-07-31</guid>
<pubDate>Thu, 31 Jul 2025 04:00:00 GMT</pubDate>
<description>Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel</description>
</item>
<item>
<title>Sage Therapeutics Announces Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/supernus-pharmaceuticals-inc/news/sage-therapeutics-announces-second-quarter-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/supernus-pharmaceuticals-inc/news/sage-therapeutics-announces-second-quarter-2025-financial-results</guid>
<pubDate>Wed, 30 Jul 2025 20:05:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., July 30, 2025--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the second quarter ended June 30, 2025.</description>
</item>
<item>
<title>Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer</title>
<link>https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-pharmaceuticals-announces-expiration-hart-scott-rodino-waiting-period-sage</link>
<guid isPermaLink="true">https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-pharmaceuticals-announces-expiration-hart-scott-rodino-waiting-period-sage</guid>
<pubDate>Mon, 28 Jul 2025 04:00:00 GMT</pubDate>
<description>ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) ("Supernus", and the "Company"), today</description>
</item>
<item>
<title>Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025</title>
<link>https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-pharmaceuticals-announce-second-quarter-2025-financial-results-and-host</link>
<guid isPermaLink="true">https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-pharmaceuticals-announce-second-quarter-2025-financial-results-and-host</guid>
<pubDate>Tue, 22 Jul 2025 04:00:00 GMT</pubDate>
<description>ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and</description>
</item>
<item>
<title>Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio</title>
<link>https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-pharmaceuticals-acquire-sage-therapeutics-strengthening-its-neuropsychiatry</link>
<guid isPermaLink="true">https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-pharmaceuticals-acquire-sage-therapeutics-strengthening-its-neuropsychiatry</guid>
<pubDate>Mon, 16 Jun 2025 04:00:00 GMT</pubDate>
<description>Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus’ leading</description>
</item>
<item>
<title>Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals</title>
<link>https://6ix.com/company/supernus-pharmaceuticals-inc/news/jay-glazer-and-wife-rosie-glazer-offer-candid-look-adhd-and-relationships-new</link>
<guid isPermaLink="true">https://6ix.com/company/supernus-pharmaceuticals-inc/news/jay-glazer-and-wife-rosie-glazer-offer-candid-look-adhd-and-relationships-new</guid>
<pubDate>Thu, 29 May 2025 04:00:00 GMT</pubDate>
<description>New video series explores the impact of ADHD on relationships and the role of Qelbree in helping Jay’s ADHD symptom management ROCKVILLE, Md., May 29, 2025</description>
</item>
<item>
<title>Supernus Announces Paragraph IV ANDA Filings for Qelbree®</title>
<link>https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-announces-paragraph-iv-anda-filings-qelbreer-2025-05-28</link>
<guid isPermaLink="true">https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-announces-paragraph-iv-anda-filings-qelbreer-2025-05-28</guid>
<pubDate>Wed, 28 May 2025 04:00:00 GMT</pubDate>
<description>ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and</description>
</item>
<item>
<title>Supernus to Participate in the 2025 Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-participate-2025-jefferies-global-healthcare-conference-2025-05-28</link>
<guid isPermaLink="true">https://6ix.com/company/supernus-pharmaceuticals-inc/news/supernus-participate-2025-jefferies-global-healthcare-conference-2025-05-28</guid>
<pubDate>Wed, 28 May 2025 04:00:00 GMT</pubDate>
<description>ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and</description>
</item>
<item>
<title>Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being ‘Ms. Represented’ in First-of-its-Kind Campaign with Supernus Pharmaceuticals</title>
<link>https://6ix.com/company/supernus-pharmaceuticals-inc/news/busy-philipps-empowers-women-adhd-go-feeling-misrepresented-being-ms-represented</link>
<guid isPermaLink="true">https://6ix.com/company/supernus-pharmaceuticals-inc/news/busy-philipps-empowers-women-adhd-go-feeling-misrepresented-being-ms-represented</guid>
<pubDate>Tue, 20 May 2025 04:00:00 GMT</pubDate>
<description>Females with ADHD frequently present with inattentive symptoms, which can be more difficult to recognize than the hyperactive and impulsive symptoms more</description>
</item>
</channel>
</rss>